Lilly forecasts weak fourth-quarter sales of weight-loss drug, shares slump

(Reuters) -Eli Lilly forecast sales of popular weight-loss drug Zepbound and related diabetes treatment Mounjaro to miss Wall Street estimates in the fourth quarter, sending the drugmaker's shares down more than 8% on Tuesday. The company said it had expected the market for the class of drugs known as incretins, which include both Zepbound and Mounjaro, to grow at a faster rate in the fourth